28.11.2013 07:49

Press Release: Novartis: New malaria target identified with potential to prevent, block, and treat multiple stages of the malaria life cycle

-1 of 2- 28 Nov 2013 06:16:00 UTC  *DJ Novartis: New malaria target identified with potential to prevent, block, and treat multiple stages of the malaria life cycle

   (MORE TO FOLLOW) Dow Jones Newswires

   November 28, 2013 01:16 ET (06:16 GMT)- - 01 16 AM EST 11-28-13

-2 of 2- 28 Nov 2013 06:16:00 UTC  Press Release: Novartis: New malaria target identified with potential to prevent, block, and treat multiple stages of the malaria life cycle

Novartis International AG / New malaria target identified with potential to prevent, block, and treat multiple stages of the malaria life cycle . Processed and transmitted by Nasdaq OMX Corporate Solutions. The issuer is solely responsible for the content of this announcement.

-- Findings published in Nature advance a Novartis goal to help eliminate malaria by identifying a new target that could lead to a treatment for multiple stages of the disease

-- Malaria kills more than 660,000 people each year, mostly African children[1]

Basel, Switzerland, November 28, 2013 - Novartis scientists have discovered a new drug target for treating malaria. The discovery, which is published online in the journal Nature,[2] identifies phosphatidylinositol-4 kinase (PfPI4K) as the target of the imidazopyrazines, a novel experimental antimalarial compound class that inhibits the development of multiple malaria-causing Plasmodium species at each stage of infection in the human host.

The on-going research to develop imidazopyrazines as a new treatment for malaria is supported by the Wellcome Trust and Medicines for Malaria Venture.

Each year malaria kills more than 660,000 people most of whom are African children. While current therapies are effective against the most common forms of malaria, recent publications suggest that the efficacy of the artemisinin-derivatives has been compromised in parts of South-East Asia. In addition, these therapies are only effective against the acute blood stages of the disease, thus leaving some patients at risk of relapse after initial treatment. Relapse prevention is especially important for P. vivax, which can form hypnozoites, dormant parasites that can persist in the liver for up to two years before reinitiating a blood-stage infection.

"This new target for malaria provides an avenue to develop the next-generation antimalarial drugs that are capable of preventing, treating and blocking the spread of malaria, a key goal of Novartis," commented Thierry Diagana, Head of the Novartis Institute for Tropical Diseases. "Compounds that inhibit this new target have the potential to complement our current malaria drug pipeline, KAE609 and KAF156, and could provide a path toward elimination of the disease."

The paper describes how scientists discovered a new class of compound with an imidazopyrazine core, to identify this new malaria target. "Our scientists carried out a large phenotypic screen which, coupled with modern genome analysis and editing tools, constitute a powerful technology platform to discover and validate drug targets for next-generation antimalarial drug discovery," said Martin Seidel, Institute Director of the Genomics Institute of the Novartis Research Foundation (GNF).

They then isolated strains of parasites that had become resistant to the compound class and identified the mutated genes. For one of these genes, PfPI4K, they went on to show through biochemical experiments that imidazopyrazines work through interaction with the ATP-binding pocket of the kinase. They also showed that these compounds are active against blood-stage field isolates of the major human malaria pathogens, P. falciparum and P. vivax, and inhibit liver-stage hypnozoites of a parasite P. cynomolgi, which is closely related to P. vivax.

Scientists from GNF and NITD collaborated with an international team of scientists from the University of California, San Diego, and Columbia University.

Broader commitment to fighting malaria: Novartis Malaria Initiative

This research is part of a broader commitment by Novartis and complements our current malaria drug pipeline, KAE609 and KAF156, in the fight against malaria. The Novartis Malaria Initiative is one of the pharmaceutical industry's largest access-to-medicines programs, focused on treatment, access, capacity-building and research & development. Over the last decade, the initiative has delivered over 600 million treatments without profit to the public sector, in more than 60 countries. Novartis believes that increasing access to medicines in developing countries is not just a matter of buying medicines and distributing them, it also requires bringing together good clinical practice, logistics management and other expertise to ensure a long-term sustainable approach to improving health. For more information visit


This press release contains expressed or implied forward-looking statements, including statements that can be identified by terminology such as "potential," "goal," "could," "experimental," "commitment," or similar expressions. Such forward-looking statements reflect the current views of the Group regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results expressed or implied by such statements. These expectations could be affected by, among other things, risks and factors referred to in the Risk Factors section of Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this press release as of this date and does not undertake any obligation to update it in the future.

About Novartis

Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, eye care, cost-saving generic pharmaceuticals, preventive vaccines and diagnostic tools, over-the-counter and animal health products. Novartis is the only global company with leading positions in all these areas. In 2012, the Group achieved net sales of USD 56.7 billion, while R&D throughout the Group amounted to approximately USD 9.3 billion (USD 9.1 billion excluding impairment and amortization charges). Novartis Group companies employ approximately 133,000 full-time-equivalent associates and operate in more than 140 countries around the world. For more information, please visit

Novartis is on Twitter. Sign up to follow @Novartis at


[1] World Health Organization,

[2] (live when embargo lifts)

# # #

Novartis Media Relations

Central media line : +41 61 324 2200 Anja von Treskow Mariellen Gallagher Novartis Global Media Relations Novartis Institutes for BioMedical Research +41 61 324 8137 (direct) +1 617 871 7665 (direct) +41 79 367 4723 (mobile) +1 617 909 9137 (mobile)


For Novartis multimedia content, please visit

For questions about the site or required registration, please contact:

Novartis Investor Relations

Central phone: +41 61 324 7944 Samir Shah +41 61 324 7944 North America: Pierre-Michel Bringer +41 61 324 1065 Stephen Rubino +1 862 778 8301 Thomas Hungerbuehler +41 61 324 8425 Jill Pozarek +1 212 830 2445 Isabella Zinck +41 61 324 7188 Susanne Donofrio +1 862 778 9257


Media release (PDF):

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Novartis International AG via Globenewswire


--- End of Message ---

Novartis International AG

P.O. Box Basel Switzerland

WKN: 904278;ISIN: CH0012005267; (END) Dow Jones Newswires

   November 28, 2013 01:16 ET (06:16 GMT)- - 01 16 AM EST 11-28-13

Nachrichten zu Novartis AG (Spons. ADRS)

  • Relevant
  • Alle
  • vom Unternehmen
  • Peer Group
  • ?

Keine Nachrichten im Zeitraum eines Jahres in dieser Kategorie verfügbar.

Eventuell finden Sie Nachrichten, die älter als ein Jahr sind, im Archiv

Um Ihnen die Übersicht über die große Anzahl an Nachrichten, die jeden Tag für ein Unternehmen erscheinen, etwas zu erleichtern, haben wir den Nachrichtenfeed in folgende Kategorien aufgeteilt:

Relevant: Nachrichten von ausgesuchten Quellen, die sich im Speziellen mit diesem Unternehmen befassen

Alle: Alle Nachrichten, die dieses Unternehmen betreffen. Z.B. auch Marktberichte die außerdem auch andere Unternehmen betreffen

vom Unternehmen: Nachrichten und Adhoc-Meldungen, die vom Unternehmen selbst veröffentlicht werden

Peer Group: Nachrichten von Unternehmen, die zur Peer Group gehören

Analysen zu Novartis AG (Spons. ADRS)

  • Alle
  • Buy
  • Hold
  • Sell
  • ?
10.11.2016Novartis BuyArgus Research Company
10.10.2016Novartis BuyChardan Capital Markets
20.09.2016Novartis BuyChardan Capital Markets
01.03.2013Novartis verkaufenVontobel Research
29.01.2013Novartis haltenHamburger Sparkasse AG (Haspa)
10.11.2016Novartis BuyArgus Research Company
10.10.2016Novartis BuyChardan Capital Markets
20.09.2016Novartis BuyChardan Capital Markets
06.01.2010Novartis "buy"SEB AG
22.10.2009Novartis buySEB AG
29.01.2013Novartis haltenHamburger Sparkasse AG (Haspa)
24.01.2013Novartis haltenFrankfurter Tagesdienst
01.03.2013Novartis verkaufenVontobel Research
24.01.2013Novartis verkaufenVontobel Research
23.01.2013Novartis verkaufenVontobel Research

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Novartis AG (Spons. ADRS) nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"

Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"

Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
mehr Analysen
Börse Stuttgart Anlegerclub

Fünf deutsche Internet-Aktien, die Sie kennen sollten!

Das Gute liegt oft so nah. Heimische Internet-Unternehmen rollen den Markt auf. Im neuen Anlegermagazin erwartet Sie ein Special über deutsche Internet-Aktien, die Sie kennen sollten.
Kostenfrei registrieren und lesen!

Novartis Peer Group News

Keine Nachrichten gefunden.

Heute im Fokus

DAX geht wenig bewegt ins Wochenende -- Wall Street schließt uneinheitlich -- Investor Icahn gibt Widerstand gegen Börsenrückkehr von Dell auf -- VW, MorphoSys, NVIDIA, Bayer im Fokus

Wechsel im GEA-Aufsichtsrat. ProSiebenSat.1-Aktie im Fokus: TV-Sender in stürmischem Fahrwasser. BlackBerry erwirbt in Milliardendeal Cyber-Sicherheits-Firma. T-Mobile-US-Finanzchef rechnet mit Sprint-Deal im zweiten Quartal. Fed plant umfassende Überprüfung ihrer Arbeitsweise.

Die 5 beliebtesten Top-Rankings

Die reichsten Länder der EU
Das sind die wohlhabendsten Länder der EU
Die besten Airlines der Welt 2018
Welche Fluggesellschaft triumphiert?
Best Global Brands 2018
Die Top 20 der wertvollsten Marken weltweit
Gut bezahlte Jobs
Bei diesen Top-Konzernen brauchen Bewerber keinen Abschluss
Das Schwarzbuch 2018/2019
Wo 2018 sinnlos Steuern verbrannt wurden
mehr Top Rankings


Horst Seehofer will sein Amt als Parteivorsitzender der CSU niederlegen aber weiterhin Bundesinnenminister bleiben. Halten Sie das für richtig? Brokerage

Online Brokerage über

Das Beste aus zwei Welten: Handeln Sie für nur 5 Euro Orderprovision* pro Trade unmittelbar aus der Informationswelt von!
Zur klassischen Ansicht wechseln
Kontakt - Impressum - Werben - Pressemehr anzeigen
Top News
Beliebte Suchen
DAX 30
Euro US-Dollar
Daimler AG710000
Deutsche Bank AG514000
NVIDIA Corp.918422
Apple Inc.865985
Wirecard AG747206
Deutsche Telekom AG555750
Aurora Cannabis IncA12GS7
PG&E Corp.851962
Volkswagen (VW) AG Vz.766403
Infineon AG623100